

4. The compound of claim 1 wherein L is -NHCO- .
5. The compound of claim 1 wherein L is -CONH- .
6. The compound of anyone of claims 1-5 wherein R^1 is optionally mono-, di-, or tri-substituted aryl.
7. The compound of anyone of claims 1-5 wherein R^1 is selected from the group consisting of optionally mono-, di-, or tri-substituted pyridinyl, pyridazinyl or triazinyl.
8. The compound of anyone of claims 1-7 wherein R^2 is optionally mono-, di-, or tri-substituted aryl.
9. The compound of anyone of claims 1-7 wherein R^2 is selected from the group consisting of optionally mono-, di-, or tri-substituted pyridinyl, pyridazinyl or triazinyl.
10. The compound of claim 1 selected from one of the examples of 1-50 described in table 1.
11. The compound of claim 1 selected from one of the examples of 51-100 described in table 1.
12. The compound of claim 1 selected from one of the examples of 101-150 described in table 1.
13. The compound of claim 1 selected from one of the examples of 151-186 described in table 1.
14. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
15. Use of a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof for the ~~in the manufacture of a medicament for treating a central nervous system disease or disorder, the method comprises administering a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is a central nervous system disease or disorder.~~
16. The use of claim 15, wherein the central nervous system disease or disorder is a cognitive, neurodegenerative, psychiatric or neurological disease or disorder.